Journals / Haseki Tıp Bülteni / 2013 / Cilt: 51 - Sayı: 2

Prognostic factors in advanced-stage non-small cell lung cancer

İleri evre küçük hücreli dışı Akciğer kanserinde prognostik faktörler

Pages
57–60
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In our study, elevated serum LDH, male gender, younger age, lower hemoglobin level, weight loss, performance status and tumor size were found to be associated with poor prognosis but the results were not statistically significant.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Lung cancer is one the most common malign tumors with poor survival.
📊
Key Findings & Data:Methods: In this retrospective study, we included 111 patients with stage IIIB and IV non-small cell lung cancer (NSCLC) who presented to our clinics between 2005 and 2006.
💡
Conclusion & Impact:Conclusion: In our study, elevated serum LDH, male gender, younger age, lower hemoglobin level, weight loss, performance status and tumor size were found to be associated with poor prognosis but the results were not statistically significant.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Lung cancer is one the most common malign tumors with poor survival. Our study evaluated the relationship between prognostic factors and survival. Methods: In this retrospective study, we included 111 patients with stage IIIB and IV non-small cell lung cancer (NSCLC) who presented to our clinics between 2005 and 2006. We investigated the relationship of survival with tumor size and histological sub-groups, levels of lactate dehydrogenase (LDH) and hemoglobin(Hb), weight loss, performance status, age, and gender. Results: Nineteen female (17.1%) and 92 male (82.9%) patients with an average age of 59.56±8.98 years were included in the study. The number of patients with stage IV and stage IIIB disease were 72 (63.9%) and 39 (36.1%), respectively. Histological subtypes were as follows: NSCLC (unspecified) -16 patients (14.4%), epidermoid carcinoma-45 (40.5%), adenocarcinoma - 41 (36.9%), large-cell carcinoma - 1(0.9%), neuroendocrine carcinoma - 1 (0.9%), adenosquamous cancer - 3 (2.7%), bronchoalveolar carcinoma - 2 (1.8%), carcinoma with neuroendocrine differentiation - 1 (0.9%) and pleomorphic carcinoma -1 patient (0.9%). No statistically significant relationship of survival with gender, age, tumor size, LDH, Hb, weight loss and performance status was observed. Only statistically significant relationship was found between survival and stage. Conclusion: In our study, elevated serum LDH, male gender, younger age, lower hemoglobin level, weight loss, performance status and tumor size were found to be associated with poor prognosis but the results were not statistically significant.

Özet

Amaç: Akciğer kanseri en sık rastlanan malign tümörlerden biri olup sağkalımı kötüdür. Sağkalımda rol oynayan literatürde 150’den fazla prognostik faktör tanımlanmıştır. Çalışmamızda prognostik faktörler ile sağkalım arasındaki ilişki değerlendirilmiştir. Yöntem: Geriye dönük yapılan çalışmamıza hastanemize 2005- 2006 yılları arasında başvuran evre IIIB ve IV Küçük Hücreli Dışı Akciğer Kanseri (KHDAK) olan toplam 111 vaka alındı. Bu vakalarda tümör çapı, laktat dehidrogenaz (LDH), hemoglobin (Hb), performans durumu, kilo kaybı, yaş, cinsiyet ve histolojik alt gruplar ile sağkalım arasındaki ilişkisi incelenmiştir. Bulgular: Çalışmamızda kadın hasta sayısı 19 (%17.1) erkek hasta sayısı 92 (%82.9) idi. Hastaların ortalama yaşı 59.56±8.98 olarak hesaplandı. Vakalarımızın 72 (%63.9)’si evre IV, 39 (%36.1)’u evre IIIB idi. Hastaların hücre tipi alt gruplarına göre dağılımı aşağıdaki gibi idi; KHDAK (sınıflandırılamayan) 16 (%14.4), epidermoid karsinom 45 (%40.5), adenokarsinom 41 (%36.9), büyük hücreli karsinom 1 (%0.9), nöroendokrin karsinom 1 (%0.9), adenoskuamöz kanser 3 (%2.7), bronkoalveolar karsinom 2 (%1.8), nöroendokrin farklılaşma gösteren karsinom 1 (%0.9), pleomorfik karsinom 1 (%0.9). Cinsiyet, yaş, tümör çapı, LDH, Hb, kilo kaybı ve performans durumu ile sağkalım arasında istatistiksel olarak anlamlı sonuçlar elde edilemedi. Sadece evre ile sağkalım arasında istatistiksel olarak anlamlı ilişki saptandı. Sonuç: Çalışmamızda yüksek serum LDH, erkek cinsiyet, genç yaş, düşük hemoglobin düzeyi, kilo kaybı, performans durumu ve tümör çapı kötü prognozla ilişkili olarak saptanmış fakat istatistiksel olarak anlamlı sonuçlar elde edilememiştir.

🔖

Cite This Article

ZİNNET, B. B., SARI, Ö. Ü., ERTURAN, S., AYDIN, G. (2013). Prognostic factors in advanced-stage non-small cell lung cancer. Haseki Tıp Bülteni, Cilt: 51 - Sayı: 2, 57–60. https://ajindex.com/articles/267933

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Geddes DM. The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 1979;73:1- 17
  2. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-9
  3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57
  4. Johnson BE. Biologic and molecular prognostic factors-- impact on treatment of patients with non-small cell lung cancer. Chest 1995;107(Suppl 6):287-90
  5. Bremnes RM, Sundstrom S, Aasebo U, at al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow- up Lung Cancer 2003;39:303-13
  6. Nugent WC, Edney MT, Hammerness PG, Dain BJ, Maurer LH, Rigas JR. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg 1997;63:193-7
  7. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 1998;16:651-7
  8. Tsai CM, Perng RP Huang WL. Lung cancer in young Chinese. Cancer Detect Prev 1988;11:235-8
  9. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26
  10. Hespanhol V, Queiroga H, Magalhães A, Santos AR, Coelho M, Marques A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995;13:253-67
  11. Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996;15:67- 77
  12. Danner BC, Didilis VN, Wiemeyer S, et al. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res 2010;30:1347-51
  13. Palomares MR, Sayre JW, Shekar KC, Lillington LM, Chlebowski RT. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996;78:2119-26
  14. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-802
  15. Kawaguchi T, Takada M, Kubo A, et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan.